Stopping a long-acting Abilify (aripiprazole) injection is different from stopping a daily tablet because the injection forms a depot in the body and continues releasing medication for an extended period. Because aripiprazole levels decline slowly, abruptly stopping injections can produce a relatively large change in drug exposure even though the medication may remain in the body for many weeks.
For people who have been taking Abilify injections for a long time and want to discontinue gradually, it may be worth discussing a slower, individualized taper with a knowledgeable prescriber rather than simply skipping the next injection.
Why Long-Acting Injections Need Special Consideration
Long-acting aripiprazole injections are designed to maintain relatively stable drug levels between doses. With repeated injections, medication from previous injections remains in the body while the next dose is administered, creating an accumulation of aripiprazole.
This means that stopping the injections does not cause the medication to disappear immediately. Instead, the body gradually eliminates both the current injection and medication remaining from previous injections.
Aripiprazole also has a much longer effective elimination time when administered as a long-acting injection than when taken orally. For example, the reported terminal half-life of Aristada is approximately 54–57 days after repeated dosing.
Because of this, changes made several weeks or months earlier can continue to influence drug levels.
A Gradual Approach
One potential approach is to reduce exposure gradually by increasing the amount of time between injections, rather than stopping injections abruptly.
For example, a person receiving Abilify Maintena 400 mg every 4 weeks might first discuss extending the interval before the next injection. Pharmacokinetic modeling has examined a progression from:
400 mg every 4 weeks → 400 mg every 7 weeks → 300 mg every 4 weeks
After reaching 300 mg, the interval can potentially be extended further before eventually transitioning to a very small oral dose and tapering the oral medication gradually. These modeled approaches were designed to produce smaller reductions in dopamine D₂ receptor occupancy than abrupt discontinuation.
This is not a one-size-fits-all schedule. A person who is sensitive to medication changes may need a considerably slower approach, with longer periods of stabilization between reductions.
Transitioning From the Injection to Oral Aripiprazole
Once the injection has been reduced and/or the dosing interval has been extended, some people may transition to a small daily oral dose of aripiprazole.
This can provide much greater control over the taper because an oral dose can be adjusted in very small increments, whereas an injection delivers a large amount of medication that cannot be removed once administered.
One published pharmacokinetic model proposed very small oral doses after the final injections, followed by gradual hyperbolic reductions. Its slower modeled approach used 5 mg of oral aripiprazole before beginning further reductions. Faster modeled approaches used 2.5 mg or 1.25 mg. These were modeling-based proposals rather than established clinical tapering guidelines.
Because residual medication from previous injections can continue to be eliminated for months, the oral dose may need to remain stable for an extended period before additional reductions are considered.
Hyperbolic Tapering
A hyperbolic taper recognizes that the relationship between dose and receptor occupancy is not linear. As the dose becomes smaller, progressively smaller reductions in the actual dose may be needed to produce similarly sized changes in receptor occupancy.
For this reason, reducing a medication by the same number of milligrams at every step may become increasingly difficult toward the end of the taper.
A gradual oral taper can therefore involve progressively smaller reductions as the dose becomes lower, with the pace adjusted according to the person's response.
What About Simply Dropping From 400 mg to 300 mg?
For Abilify Maintena, 300 mg and 400 mg are established monthly maintenance doses. A reduction from 400 mg to 300 mg is therefore a possible prescribing-dose reduction, but it represents a 25% reduction in the injected dose.
For someone who is highly sensitive to medication changes, even a 25% reduction may be too large to tolerate comfortably.
Extending the interval between injections can provide another way of reducing overall exposure without immediately making a large reduction in the amount contained in each injection.
A prescriber may therefore consider both dose size and time between doses, rather than looking at the milligram amount alone.
Go Slowly and Allow Time to Adjust
Because long-acting aripiprazole remains in the body for a prolonged period, it can take considerably longer to see the full effect of a reduction.
It is therefore important not to assume that feeling well immediately after a reduction means the change has been completely tolerated. Conversely, symptoms appearing weeks later do not necessarily mean that the previous reduction was unrelated.
Allowing adequate time between reductions can make it easier to determine whether symptoms are related to the taper and can prevent multiple changes from overlapping.
If significant withdrawal symptoms or other difficulties develop, holding at the current level for longer may be appropriate to discuss with a prescriber rather than automatically making another reduction.
Withdrawal Symptoms Can Occur
Some people experience symptoms when reducing or stopping aripiprazole, particularly after long-term use or a rapid reduction. Possible symptoms can include:
- anxiety or inner agitation
- insomnia or changes in sleep
- restlessness or akathisia
- nausea or gastrointestinal symptoms
- dizziness
- sweating
- headaches
- sensory changes
- mood changes
- unusual movements or other neurological symptoms
Withdrawal symptoms can overlap with symptoms of the condition for which the medication was originally prescribed, so it can sometimes be difficult to determine what is happening.
A careful taper, symptom tracking, and adequate stabilization time can help provide a clearer picture.
Important Considerations With Long-Acting Injections
There are several different long-acting aripiprazole products, including Abilify Maintena, Abilify Asimtufii, and Aristada, and they do not have identical dosing schedules or pharmacokinetic properties.
For example, Aristada is available in several dosing intervals, including monthly, every 6 weeks, and every 2 months, depending on the formulation and dose. Its prescribing information reports a terminal half-life of approximately 54–57 days after repeated dosing.
Therefore, a taper should be based on the specific injection, dose, dosing interval, length of treatment, and individual response rather than applying another person's schedule.
The Goal Is a Manageable Reduction, Not a Race to Zero
The purpose of a gradual taper is to give the nervous system time to adapt as medication exposure decreases.
There is no requirement to reduce the medication according to a predetermined timetable if the person is struggling. A slower taper, longer holding period, or smaller reduction may be more manageable than repeatedly pushing through severe symptoms.
Once a person reaches the oral stage, the medication can generally be reduced in much smaller amounts, allowing the final portion of the taper to be especially gradual.
Remember
Long-acting injections cannot be removed once administered. Each injection represents a substantial commitment of medication that will continue releasing over an extended period.
For that reason, anyone considering a taper should work with a knowledgeable prescriber to plan ahead, make one change at a time, and have a strategy for managing symptoms if the reduction proves too difficult.
This information is educational and is not a substitute for individualized medical care. Do not change the dose or timing of an antipsychotic injection without discussing it with your prescriber.
TaperCommunity